The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
复制标题
三级淋巴结构的存在为乳腺癌患者的临床病理特征和预后提供了新的见解
DOI：
10.3389/fimmu.2022.868155
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
三级淋巴样结构（TLS）已被证明是几种实体恶性肿瘤良好临床结局和免疫治疗反应的预测生物标志物。然而，TLS在乳腺癌（BC）患者中的作用仍然存在争议。本研究的目的是探讨在BC的临床病理和预后意义的TLS。鉴于检测和定量TLS的独特困难，使用基于癌症基因组图谱（TCGA）BC队列的TLS相关基因签名来验证和补充我们的结果。系统检索电子平台（PubMed、Web of Science、EMBASE、科克伦图书馆、CNKI和万方），以识别截至2022年1月11日的相关研究。我们计算了合并比值比（OR）和95%置信区间（CI），以确定临床病理参数和TLS之间的关系。还计算了合并风险比（HR）和95% CI，以评价TLS的预后意义。基于TCGA BC队列的TLS签名被应用于验证和补充我们的结果。15项研究（3，898例患者）有资格入组我们的研究。综合分析表明，TLS的存在与无病生存期（DFS）（HR = 0.61，95% CI：0.41-0.90，p < 0.05）和总生存期（OS）（HR = 1.66，95% CI：1.26-2.20，p < 0.001）的改善相关。此外，TLR的存在与早期肿瘤TNM分期和高肿瘤浸润淋巴细胞正相关。TLS的存在与人表皮生长因子受体2（HER-2）和Ki-67呈正相关，但与雌激素和孕激素受体的状态呈负相关。同时，我们的研究发现，高TLS签名组的肿瘤免疫微环境比低TLS签名组更有利。一致地，高TLS签名组中的BC患者与低TLS签名组中的BC患者相比表现出更好的生存结局，这表明TLS可能是有利的预后生物标志物。TLS的存在为BC患者的临床病理特征和预后提供了新的见解，而讨论的因素限制了本研究的证据质量。我们期待一致的方法来定义和表征TLS，以及更多高质量的前瞻性临床试验，旨在验证TLS单独或与其他标志物组合的价值。
Tertiary lymphoid structures (TLSs) have been proven to be predictive biomarkers of favorable clinical outcomes and response to immunotherapies in several solid malignancies. Nevertheless, the effect of TLSs in patients with breast cancer (BC) remains controversial. The objective of the current study is to investigate the clinicopathological and prognostic significance of TLSs in BC. Given the unique difficulties for detecting and quantifying TLSs, a TLS-associated gene signature based on The Cancer Genome Atlas (TCGA) BC cohort was used to validate and supplement our results. Electronic platforms (PubMed, Web of Science, EMBASE, the Cochrane Library, CNKI, and Wanfang) were searched systematically to identify relevant studies as of January 11, 2022. We calculated combined odds ratios (ORs) with 95% confidence intervals (CIs) to determine the relationship between clinicopathological parameters and TLSs. The pooled hazard ratios (HRs) and 95% CIs were also calculated to evaluate the prognostic significance of TLSs. The TLS signature based on the TCGA BC cohort was applied to validate and supplement our results. Fifteen studies with 3,898 patients were eligible for enrollment in our study. The combined analysis indicated that the presence of TLSs was related to improved disease-free survival (DFS) (HR = 0.61, 95% CI: 0.41–0.90, p < 0.05) and overall survival (OS) (HR = 1.66, 95% CI: 1.26–2.20, p < 0.001). Additionally, the presence of TLSs was positively correlated with early tumor TNM stage and high tumor-infiltrating lymphocytes. TLS presence was positively related to human epidermal growth factor receptor 2 (HER-2) and Ki-67 but inversely correlated with the status of estrogen and progesterone receptor. Simultaneously, our study found that tumor immune microenvironment was more favorable in the high-TLS signature group than in the low-TLS signature group. Consistently, BC patients in the high-TLS signature group exhibited better survival outcomes compared to those in the low-TLS signature group, suggesting that TLSs might be favorable prognostic biomarkers. TLS presence provides new insight into the clinicopathological features and prognosis of patients with BC, whereas the factors discussed limited the evidence quality of this study. We look forward to consistent methods to define and characterize TLSs, and more high-quality prospective clinical trials designed to validate the value of TLSs alone or in combination with other markers.
登录
查看更多内容
影响因子：
64.8
作者：
Helmink BA;Reddy SM;Gao J;Zhang S;Basar R;Thakur R;Yizhak K;Sade-Feldman M;Blando J;Han G;Gopalakrishnan V;Xi Y;Zhao H;Amaria RN;Tawbi HA;Cogdill AP;Liu W;LeBleu VS;Kugeratski FG;Patel S;Davies MA;Hwu P;Lee JE;Gershenwald JE;Lucci A;Arora R;Woodman S;Keung EZ;Gaudreau PO;Reuben A;Spencer CN;Burton EM;Haydu LE;Lazar AJ;Zapassodi R;Hudgens CW;Ledesma DA;Ong S;Bailey M;Warren S;Rao D;Krijgsman O;Rozeman EA;Peeper D;Blank CU;Schumacher TN;Butterfield LH;Zelazowska MA;McBride KM;Kalluri R;Allison J;Petitprez F;Fridman WH;Sautès-Fridman C;Hacohen N;Rezvani K;Sharma P;Tetzlaff MT;Wang L;Wargo JA
通讯作者：
Wargo JA
影响因子：
7.4
作者：
Chao, Xue;Liu, Lili;Yun, Jingping
通讯作者：
Yun, Jingping
影响因子：
32.4
作者：
Joshi NS;Akama-Garren EH;Lu Y;Lee DY;Chang GP;Li A;DuPage M;Tammela T;Kerper NR;Farago AF;Robbins R;Crowley DM;Bronson RT;Jacks T
通讯作者：
Jacks T
三级淋巴结构和肿瘤浸润淋巴细胞在口腔鳞癌中的预后价值
影响因子：
14.9
作者：
Li, Qunxing;Liu, Xiangqi;Wang, Zhi
通讯作者：
Wang, Zhi
影响因子：
5
作者：
Alberts E;Wall I;Calado DP;Grigoriadis A
通讯作者：
Grigoriadis A